
Please try another search
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Lawrence B. Gozlan | 46 | 2020 | Independent Non-Executive Director |
Patricio G. Schlottmann | - | 2024 | Member of Medical Advisory Board |
Carl D. Regillo | - | 2024 | Member of Medical Advisory Board |
Andrew K. Chang | - | 2024 | Member of Medical Advisory Board |
Arshad M. Khanani | 46 | 2024 | Chief Medical Advisor & Chairman of Medical Advisory Board |
Anat Loewenstein | - | 2024 | Member of Medical Advisory Board |
Frank G. Holz | - | 2024 | Member of Medical Advisory Board |
David S. Boyer | - | 2024 | Member of Medical Advisory Board |
Eric Souied | - | 2024 | Member of Medical Advisory Board |
Dante Pieramici | - | 2024 | Member of Medical Advisory Board |
Tien Y. Wong | - | 2024 | Member of Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review